Bioxytran Reports Positive Phase 2 Results for ProLectin-M, Demonstrating 100% Viral Clearance

summarizeSummary

Bioxytran reported compelling positive Phase 2 clinical trial results for ProLectin-M, showing 100% viral clearance by Day 7 in treated subjects, paving the way for late-stage development.

check_boxKey Events

• Positive Phase 2 Results for ProLectin-M

  Bioxytran announced successful completion of its Phase 2 randomized, double-blind, placebo-controlled trial for ProLectin-M in acute viral infection.

• 100% Viral Clearance Achieved

  The trial demonstrated complete elimination of viral load in 100% of treated subjects by Day 7, a statistically significant outcome (p = .001) compared to the placebo group.

• Rapid and Sustained Clearance

  Results indicated rapid viral clearance, with a significant proportion of treated subjects achieving viral non-detection by Day 3 and no viral rebounds during a 14-day post-treatment observation period.

• Novel Mechanism of Action

  ProLectin-M's galectin antagonist mechanism interferes with viral entry at the cell surface, representing a fundamentally different strategy in antiviral therapy.

auto_awesomeAnalysis

Bioxytran, a clinical-stage biotechnology company, announced highly positive Phase 2 clinical trial results for its lead antiviral therapeutic, ProLectin-M. The trial demonstrated complete elimination of viral load in 100% of treated subjects by Day 7, a statistically significant outcome compared to placebo (p = .001). This strong data significantly de-risks the drug's development, validating its novel mechanism of action which interferes with viral entry at the cell surface. The company plans to advance regulatory discussions for late-stage clinical development, which is a critical step towards potential commercialization and could be transformative for this micro-cap biotech.